PD-027 BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Hielscher, J., Lerch, M., Scheithauer, W., Jagenburg, A., Held, S., Modest, D., Jung, A., Kirchner, T., Heinemann, V.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984175/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw200.27
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki